Back to company

Devopharma ApS: Financial statements 2022

CVR: 38968254

Devopharma ApS (CVR 38968254) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -3,125 and a net result of DKK -3,125 compared with DKK -3,125 the year before. Equity amounted to DKK 34,375. The solvency ratio was 34.4%.

Gross Profit
-3,125 kr.
Profit/Loss
-3,125 kr.
Equity
34,375 kr.
Total Assets
100,000 kr.
Employees
0

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2022--3 t.-3 t.34 t.0
2021--3 t.-3 t.38 t.0
2020--3 t.-3 t.41 t.0
2019--3 t.-3 t.44 t.0

Official annual report

View the official annual report directly on the page with a Pro subscription.

Keep an eye on Devopharma ApS

Get notified instantly about new financial statements, ownership changes, management changes and status changes.

Set up monitoring

Events in 2022

Devopharma ApS: The 2021 annual report is outJul 4, 2022

Devopharma ApS has published its annual report for 2021. Gross profit came to DKK -3,125, and the net result was DKK -3,125.

About Devopharma ApS

Devopharma ApS is a Danish company of the type Anpartsselskab based in Charlottenlund, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Henrik Nakskov and Søren Luplau-Pagh. The company's owners include JARCO HOLDING ApS, HN HOLDING 2010 ApS and Friendly Holding ApS. In 2025, the company reported a gross profit of DKK -3,125 and a net result of DKK -3,125 compared with DKK -3,125 the year before. Equity amounted to DKK 25,000.

Other financial years